The contract signing is a routine operational milestone but lacks concrete financial terms or timelines. Monitor for subsequent 6-K filings disclosing trial initiation, patient enrollment updates, and any financing events to fund the Phase 2 study.
Price Chart
Executive Summary
Quantum BioPharma announced it has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business (PPD) to implement its Phase 2 trial of Lucid-MS for progressive multiple sclerosis. This follows prior FDA clearance to proceed and marks the initiation of formal study start-up activities, but no financial terms, trial timelines, or enrollment targets were disclosed.
Key Facts
- Quantum BioPharma entered a Study Start-Up Agreement with Thermo Fisher Scientific's PPD clinical research business for the Phase 2 Lucid-MS trial in multiple sclerosis.
- The Phase 2 trial is a randomized, double-blind, placebo-controlled study evaluating efficacy, safety, and tolerability of Lucid-MS in progressive forms of MS.
- No financial terms, trial start date, enrollment target, or duration were disclosed in the filing.
- The MS therapeutics market is projected to exceed $38 billion by 2030 per Grand View Research, and MS affects ~2.8 million people worldwide.
- Quantum retains 19.48% ownership of Unbuzzd Wellness Inc. and is entitled to 7% royalty on sales until $250 million, then 3% in perpetuity.
Financial Impact
No financial terms of the contract disclosed; no revenue, EPS, or deal value provided. The filing contains no financial data.
Risk Factors
- Clinical trial risks: delays in site activation, patient recruitment, or retention; possibility that results may not demonstrate safety or efficacy.
- Dependence on third-party CRO (PPD/Thermo Fisher for trial execution.
- No disclosed financing commitment disclosed; company may need additional capital to complete the Phase 2 study.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006429 |
| Document: f6k_100526.htm | 0001171843-26-006429 |
| Document: 0001171843-26-006429-index-headers.html | 0001171843-26-006429 |
| Document: 0001171843-26-006429-index.html | 0001171843-26-006429 |
| Document: 0001171843-26-006429.txt | 0001171843-26-006429 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.21 (−28.94%) |
Oct 6, 2026 20d ago | 6-K | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 6, 2026 20d ago | Press Release | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.21 (−32.42%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.21 (−44.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.21 (−36.13%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers